Skip to main content
SpringerLink
Log in

Dermatological

  • Chapter
PET-CT and PET-MRI in Oncology

Part of the book series: Medical Radiology ((Med Radiol Diagn Imaging))

  • 2681 Accesses

Abstract

FDG PET/CT is a valuable tool to evaluate many dermatologic malignancies, especially in more advanced disease states. The literature supporting the use of FDG PET/CT in staging, restaging, or treatment assessment is greatest in melanoma. When compared to conventional imaging, FDG PET/CT is superior due to better lesion sensitivity and the extended imaging coverage. Changes in management due to PET/CT results are frequently reported in more than 30% of patients with skin cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abeloff MD et al (eds) (2008) Abeloff’s clinical oncology. 4th edn. Churchill Livingstone Elsevier, Philadelphia, p 2592

    Google Scholar 

  • Akcali C et al (2007) Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT. J Int Med Res 35(4):547–553

    PubMed  CAS  Google Scholar 

  • Aukema T et al (2010) Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases. Ann Surg Oncol 17(10):2773–2778

    Article  PubMed  Google Scholar 

  • Balch CM et al (1983) A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol Off J Amer Soc Clin Oncol 1(2):126–134

    CAS  Google Scholar 

  • Balch CM et al (2001) Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging. J Clin Oncol 19(16):3622–3634

    PubMed  CAS  Google Scholar 

  • Blumer SL et al (2009) Cutaneous and subcutaneous imaging on FDG-PET: benign and malignant findings. Clin Nucl Med 34(10):675–683

    Article  PubMed  Google Scholar 

  • Bosserhoff A (ed) (2011) Melanoma development: molecular biology. Springer-Verlag, New York, p 390

    Google Scholar 

  • Cho SB et al (2005) Fluorodeoxyglucose positron emission tomography in cutaneous squamous cell carcinoma: retrospective analysis of 12 patients. Dermatol Surg 31(4):442–446 (Discussion 446-7)

    PubMed  CAS  Google Scholar 

  • Concannon R, Larcos GS, Veness M (2010) The impact of 18F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: results from Westmead Hospital, Sydney, Australia. J Am Acad Dermatol 62(1):76–84

    Article  PubMed  Google Scholar 

  • Da Forno PD, Saldanha GS (2011) Molecular aspects of melanoma. Clin Lab Med 31(2):331–343

    Article  PubMed  Google Scholar 

  • Denoyer D et al (2010) High-contrast PET of melanoma using (18)F-MEL050, a selective probe for melanin with predominantly renal clearance. J Nucl Med 51(3):441–447

    Article  PubMed  CAS  Google Scholar 

  • Denoyer D et al (2011) Improved detection of regional melanoma metastasis using 18F–6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration. J Nucl Med 52(1):115–122

    Article  PubMed  Google Scholar 

  • Dimitrakopoulou-Strauss A, Strauss LG, Burger C (2001) Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis. J Nucl Med 42(2):248–256

    PubMed  CAS  Google Scholar 

  • Dirisamer A et al (2008) Dual-time-point FDG-PET/CT for the detection of hepatic metastases. Mol Imag Biology 10(6):335–340

    Article  Google Scholar 

  • Edge S et al (eds) (2009) AJCC cancer staging manual, 7th edn. Springer, New York

    Google Scholar 

  • Elstrom R et al (2003) FDG-PET scanning in lymphoma by WHO classification. Blood 101(10):3875–3876

    Article  PubMed  CAS  Google Scholar 

  • Essler M et al (2011) Prognostic value of [18F]-fluoro-deoxy-glucose PET/CT, S100 or MIA for assessment of cancer-associated mortality in patients with high risk melanoma. PLoS ONE 6(9):e24632

    Google Scholar 

  • Etchebehere EC et al (2010) Impact of [F-18] FDG-PET/CT in the restaging and management of patients with malignant melanoma. Nucl Med Commun 31(11):925–930

    Article  PubMed  Google Scholar 

  • Feeney J et al (2010) Characterization of T-cell lymphomas on FDG PET/CT. Am J Roentgenol 195(2):333–340

    Article  Google Scholar 

  • Fosko SW et al (2003) Positron emission tomography for basal cell carcinoma of the head and neck. Arch Dermatol 139(9):1141–1146

    Article  PubMed  Google Scholar 

  • Freton A et al (2011) Initial PET/CT staging for choroidal melanoma: AJCC correlation and second nonocular primaries in 333 patients. Eur J Ophthalmol 22(2):236–243

    Google Scholar 

  • Friedman KP, Wahl RL (2004) Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med 34(4):242–253

    Article  PubMed  Google Scholar 

  • Gritters L et al (1993) Initial assessment of positron emission using 2-fluorine-18-fluoro-2-deoxy-d-glucose in the imaging of malignant melanoma. J Nucl Med 34:1420–1427

    PubMed  CAS  Google Scholar 

  • Gulec SA et al (2003) The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med 28(12):961–965

    Article  PubMed  Google Scholar 

  • Habif TP (2010) Clinical dermatology. 5th edn. Elsevier, Mosby

    Google Scholar 

  • Haerle SK et al (2011) The value of (18)F-FDG-PET/CT imaging for sinonasal malignant melanoma. Eur Arch Otorhinolaryngol 269(1):127–33

    Google Scholar 

  • Hamid O et al (2011) Systemic treatments of metastatic melanoma: new approaches. J Surg Onc 104:425–429

    Google Scholar 

  • Hocker T, Tsao H (2007) Ultraviolet radiation and melanoma: a systematic review and analysis or reported sequence variants. Hum Mutat 28(6):578–588

    Article  PubMed  CAS  Google Scholar 

  • Hodi F et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723

    Article  PubMed  CAS  Google Scholar 

  • Hofman MS et al (2007) Assessing response to chemotherapy in metastatic melanoma with FDG PET: early experience. Nucl Med Commun 28(12):902–906

    Article  PubMed  Google Scholar 

  • Iagaru A et al (2006) Merkel cell carcinoma: Is there a role for 2-deoxy-2-[f-18]fluoro-d-glucose-positron emission tomography/computed tomography? Mol Imag Biology : MIB : Off Publ Acad Mol Imag 8(4):212–217

    CAS  Google Scholar 

  • Jimenez-Requena F et al (2010) Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma. Eur J Nucl Med Mol Imag 37:284–300

    Article  Google Scholar 

  • Kako S et al (2007) FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 18:1685–1690

    Article  PubMed  CAS  Google Scholar 

  • Kalady MF et al (2003) Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg 238(4):528–535 Discussion 535–7

    PubMed  Google Scholar 

  • Kalkanis D et al (2011) F-18 FDG PET positive hilar and mediastinal lymphadenopathy mimicking metastatic disease in a melanoma patient treated with interferon-alpha-2b. Clin Nucl Med 36(2):154–155

    Article  PubMed  Google Scholar 

  • Kern K (1991) [14C]deoxyglucose uptake and imaging in malignant melanoma. J Surg Res 50:643–647

    Article  PubMed  CAS  Google Scholar 

  • Kim J-S et al (2010) Before and after treatment 18F-FDG PET/CT images in a patient with cutaneous T-cell lymphoma. Eur J Nucl Med Mol Imag 37:1995

    Article  Google Scholar 

  • Krug B et al (2008) Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology 249(3):836–844

    Article  PubMed  Google Scholar 

  • Kumar R et al (2006) 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma. Br J Dermatol 155:357–363

    Article  PubMed  CAS  Google Scholar 

  • Kuo PH et al (2008a) FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. Mol Imag Biol 10:74–81

    Article  Google Scholar 

  • Kuo PH et al (2008b) FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial. Mol Imag Biol 10:306–314

    Article  Google Scholar 

  • Kurli M, Chin K, Finger PT (2008) Whole-body 18 FDG PET/CT imaging for lymph node and metastatic staging of conjunctival melanoma. Br J Ophthalmol 92(4):479–482

    Article  PubMed  CAS  Google Scholar 

  • Lachiewicz AM et al (2008) Epidemiologic support for melanoma heterogeneity using the surveillance, epidemiology, and end results program. J Invest Dermatol 128(5):1340–1342

    Article  PubMed  CAS  Google Scholar 

  • Lamarre ED et al (2011) Role of positron emission tomography in management of sinonasal neoplasms-a single institution’s experience. Amer J Otolaryngol. PMID 21925763 [Epub ahead of print]

    Google Scholar 

  • Lampreave JL et al (1998) PET evaluation of therapeutic limb perfusion in Merkel’s cell carcinoma. J Nucl Med 39(12):2087–2090

    PubMed  CAS  Google Scholar 

  • Laver NV, McLaughlin ME, Duker JS (2010) Ocular melanoma. Arch Pathol Lab Med 134(12):1778–1784

    PubMed  Google Scholar 

  • Leong SP et al (2011) Cutaneous melanoma: a model to study cancer metastasis. J Surg Onc 103:538–549

    Article  Google Scholar 

  • Lindholm P et al (1995) Carbon-11-methionine PET imaging of malignant melanoma. J Nucl Med 36(10):1806–1810

    PubMed  CAS  Google Scholar 

  • Maury F et al (2011) Interest of (18)F-FDG PET-CT scanning for staging and management of merkel cell carcinoma: a retrospective study of 15 patients. J Eur Acad Dermatol Venereol doi: 10.1111/j.1468-3083.2011.03994.x

  • Mercier GA, Alavi A, Fraker DL (2001) FDG positron emission tomography in isolated limb perfusion therapy in patients with locally advanced melanoma: preliminary results. Clin Nucl Med 26(10):832–836

    Article  PubMed  CAS  Google Scholar 

  • Metser U, Even-Sapir E (2007) Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin Nucl Med 37(3):206–222

    Article  PubMed  Google Scholar 

  • Metser U et al (2007) Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence. Am J Roentgenol 189(5):1203–1210

    Article  Google Scholar 

  • Mishima Y et al (1997) In vivo diagnosis of human malignant melanoma with positron emission tomography using specific melanoma-seeking 18F-DOPA analogue. J Neurooncol 33(1–2):163–169

    Article  PubMed  CAS  Google Scholar 

  • Nieder C, Grosu AL (2005) Response monitoring by positron emission tomography during radiotherapy of a squamous cell skin carcinoma. Onkologie 28(10):505–507

    Article  PubMed  Google Scholar 

  • Niederkohr RD et al (2007) Clinical value of including the head and lower extremities in 18F-FDG PET/CT imaging for patients with malignant melanoma. Nucl Med Commun 28(9):688–695

    Article  PubMed  Google Scholar 

  • Peloschek P et al (2010) Diagnostic imaging in Merkel cell carcinoma: lessons to learn from 16 cases with correlation of sonography, CT, MRI and PET. Eur J Radiol 73(2):317–323

    Article  PubMed  Google Scholar 

  • Pfannenberg C et al (2007) Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 43(3):557–564

    Article  PubMed  Google Scholar 

  • Pfluger T et al (2011) PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT. Eur J Nucl Med Mol Imag 38(5):822–831

    Article  Google Scholar 

  • Plettenberg A et al (1995) Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene in situ and in cell culture. Am J Pathol 146(3):651–659

    PubMed  CAS  Google Scholar 

  • Querellou S et al (2010) Clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs in patients with malignant melanoma. Nucl Med Commun 31(9):766–772

    Article  PubMed  Google Scholar 

  • Quevado W, Szabo GJ (1969) Influence of age and UV on the populations of dopa-positive melanocytes in human skin. J Invest Dermatol 52(3):287–290

    Google Scholar 

  • Reinhardt MJ et al (2006) Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 24(7):1178–1187

    Article  PubMed  Google Scholar 

  • Ren G, Pan Y, Cheng Z (2010) Molecular probes for malignant melanoma imaging. Curr Pharm Biotechnol 11(6):590–602

    Article  PubMed  CAS  Google Scholar 

  • Ribas A et al (2010) Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med 51(3):340–346

    Article  PubMed  CAS  Google Scholar 

  • Robert C et al (2011) Ipilimumab plus dacarbazine for previously treated metastatic melanoma. N Engl J Med 364:2517–2526

    Article  PubMed  CAS  Google Scholar 

  • Seetharamu N, Ott PA, Pavlick AC (2010) Mucosal melanomas: a case-based review of the literature. The Oncologist 15(7):772–781

    Article  PubMed  Google Scholar 

  • Shapiro M et al (2002) Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas. J Am Acad Dermatol 47(4):623–628

    Article  PubMed  Google Scholar 

  • Society AC (2011a) Cancer Facts & Figures 2011. American Cancer Society, Atlanta

    Google Scholar 

  • Society AC (2011b) Melanoma skin cancer. In: American Cancer Society, A.C. Society, Editor 2011, American Cancer Society, Atlanta

    Google Scholar 

  • Spraul CW, Lang GE, Lang GK (2001) Value of positron emission tomography in the diagnosis of malignant ocular tumors. Ophthalmologica. J Int d’ophtalmologie. Int J Ophthalmol. Zeitschrift fur Augenheilkunde 215(3):163–168

    Article  CAS  Google Scholar 

  • Strobel K et al (2007) High risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 244(2):566–574

    Article  PubMed  Google Scholar 

  • Strobel K et al (2008) Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B. Eur J Nucl Med Mol Imag 35(10):1786–1795

    Article  Google Scholar 

  • Strobel K et al (2009) Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. Eur J Nucl Med Mol Imag 36(11):1774–1782

    Article  CAS  Google Scholar 

  • Talbot J-N et al (2005) 6-[F-18]Fluoro-L-DOPA positron emission tomography in the imaging of merkel cell carcinoma: preliminary report of three cases with 2-Deoxy-2-[F-18]Fluoro-d-glucose positron emission tomography or pentetreotide-(111In) SPECT data. Mol Imaging Biol 7:257–261

    Article  PubMed  Google Scholar 

  • Tsai EY et al (2006) Staging accuracy in mycosis fungoides and Sezary syndrome using positron emission tomography and computed tomography. Arch Dermatol 142:577–584

    Article  PubMed  Google Scholar 

  • Uren RF et al (2011) Guidelines for lymphoscintigraphy and F18 FDG PET scans in melanoma. J Surg Onc 104:405–419

    Google Scholar 

  • Valencak J et al (2004) Positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose in primary cutaneous T-cell lymphomas. Haematologica 89(1):115–116

    PubMed  Google Scholar 

  • Valk P et al (1996) Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 23(6):737–743

    Article  PubMed  CAS  Google Scholar 

  • Wagner J et al (2001) FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Onc 77(4):237–242

    Article  CAS  Google Scholar 

  • Wahl R et al (1991) 18F–2-deoxyglucose-2-fluoro-d-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer 67:1544–1550

    Article  PubMed  CAS  Google Scholar 

  • Ware R et al (2011) First human study of N-(2-(diethylamino)ethyl)-6-[F-18]fluoropyridine-3-carboxamide (MEL050). J Nucl Med 52(Suppl 1):415

    Google Scholar 

  • Wehrli NE et al (2007) Determination of age-related changes in structure and function of skin, adipose tissue, and skeletal muscle with computed tomography, magnetic resonance imaging, and positron emission tomography. Semin Nucl Med 37(3):195–205

    Article  PubMed  Google Scholar 

  • Wong HH, Wang J (2010) Merkel cell carcinoma. Arch Pathol Lab Med 134(11):1711–1716

    PubMed  Google Scholar 

  • Wong CO, Pham AN, Dworkin HJ (2000) F-18 FDG accumulation in an octreotide negative Merkel cell tumor. Clin Positron Imag 3(2):71–73

    Article  Google Scholar 

  • Yang J (2011) Melanoma vaccines. Cancer J 17(5):277–282

    Article  PubMed  CAS  Google Scholar 

  • Yu L et al (1999) Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 86:617–627

    Article  PubMed  CAS  Google Scholar 

  • Zwald FOR, Brown M (2011) Skin cancer in solid organ transplant recipients: advances in therapy and management. part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 65(2):253–261

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Khalil Salman, MD, and Robert Lucaj, MD, for their help in preparing some of the cases.

Author information

Authors and Affiliations

  1. Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA

    David Brandon & Bruce Barron

Authors
  1. David Brandon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruce Barron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Brandon .

Editor information

Editors and Affiliations

  1. Rochester, 55901, Minnesota, USA

    Patrick Peller

  2. , Division of Neuroradiology, Boston University School of Medicine, Boston, 02493, Massachusetts, USA

    Rathan Subramaniam

  3. Dept. Radiology, Boston University Medical Center, E. Newton St. 88, Boston, 02118, Massachusetts, USA

    Ali Guermazi

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Brandon, D., Barron, B. (2012). Dermatological. In: Peller, P., Subramaniam, R., Guermazi, A. (eds) PET-CT and PET-MRI in Oncology. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2011_498

Download citation

  • DOI: https://doi.org/10.1007/174_2011_498

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-01138-2

  • Online ISBN: 978-3-642-01139-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation